Posted by AGORACOM
at 8:12 AM on Tuesday, April 20th, 2021
Mr. Wolfgang Probst appointed as the Chief Operations Officer (COO) of XPhyto
Addition of Mr. Manfred Buchberger as the Head of Corporate Development
XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) (“XPhyto” or the “Company”) is pleased to announce the appointment of Mr. Wolfgang Probst as the Chief Operations Officer (COO) of XPhyto and the addition of Mr. Manfred Buchberger as the Head of Corporate Development at XP Diagnostics GmbH (“XP Diagnostics”), a wholly owned German subsidiary of the Company. With European CE-IVD approval announced March 18, 2021, for the Company’s lead diagnostic product, Covid-ID Lab, XPhyto continues to enhance its commercial team as it anticipates near-term distribution and sales.
Mr. Probst is an experienced management and finance consultant with expertise in mergers and acquisitions, corporate re-organizations, and divestitures. He has a proven track record of leadership, strategic planning, and organizational restructuring having guided multiple startups from inception to financial success. Mr. Probst was responsible for successfully structuring XPhyto’s European operations and establishing associated partnerships and collaborations, both commercial and academic. As the newly appointed COO of XPhyto, Mr. Probst will be responsible for managing the Company’s global operations. Mr. Probst will remain a director of XPhyto and the managing director of XP Diagnostics.
Mr. Buchberger is a global leader in the medical diagnostics industry. For almost a decade, he was the CEO and a member of the Global Management Board of a major European medical diagnostics and analytics company with annual revenues of over 600 million Euro. His addition to the Company brings decades of diagnostics industry experience focused on international business development, sales, marketing, and product management. Mr. Buchberger has successfully created, implemented, and managed business growth strategies across Europe, North and South America, Middle East and Asia, including the successful launch of new medical diagnostic products.
On March 18, 2021, XPhyto announced European commercial approval of Covid-ID Lab, a rapid 25-minute point-of-care PCR test for COVID-19. Mr. Probst and Mr. Buchberger will be responsible for executing the global product launch and businesses development of Covid-ID Lab.
Covid-ID Lab is a multiplex viral RNA probe kit based on the reverse transcriptase-polymerase chain reaction (RT-PCR) method. Covid-ID Lab requires only a single 20-minute PCR thermal cycle for assay performance without prior RNA extraction as part of the sample preparation. Many widely available standard PCR instruments are suitable to run the test. Results are collected after the PCR cycle via easy-to-read optical indicator strips on a simple fluidics platform. The elimination of RNA extraction for sample preparation reduces cross-contamination risk and minimizes the need for lab materials and trained personnel. The rapid results, minimal laboratory equipment, and ease of use are expected to translate into reduced operating costs, greater convenience and portability.
Posted by AGORACOM
at 9:51 AM on Tuesday, April 13th, 2021
TORONTO , April 13, 2021 /CNW/ – Predictiv AI Inc. ( TSXV: PAI) (OTC: INOTF) (FSE: 71TA ) (” Predictiv AI ” or the ” Company “), a software and solutions provider in the artificial intelligence markets, is pleased to announce that it has entered into a consultancy agreement, effective immediately, with F2 Factor (“F2”) to provide strategic support services to the Predictiv AI leadership team, and to increase sales and distribution across brands and products.
As a leader in multichannel marketing, sales, and distribution, F2 Factor is a firm which works in tandem with leading businesses to build and execute their sales strategy. The firm is led by Mark Collins who will be working directly with the leadership team at Predictiv AI.
As a seasoned executive, Mark has built a track record of success, winning numerous awards throughout his career with GE and Cisco. Mark has played a leadership role in building multiple $100m franchises within global companies and worked with many start-up and scale-up companies over the years.
“Predictiv AI has already demonstrated an ability to bring cutting-edge technology to market at the right time to set the foundation for enabling intelligent infrastructure and controls for shared spaces that are game changing”, said Mark Collins, President of F2 Factor.
Posted by AGORACOM-JC
at 6:25 PM on Monday, April 12th, 2021
Predictiv AI’s proprietary artificial intelligence and machine learning platform provides predictive and prescriptive solutions in the public safety sector.
Its flagship product is its ThermalPass temperature scanning devices, which use cutting edge tech to mitigate the spread of contagions in public places, such as factories, supermarkets, schools, office buildings, mass-transit stations, hospitals and long-term care facilities.
24 medical grade sensors
1,200 readings per second
1 person / second
Received orders for 90+ units of ThermalPass following commercial launch in October 2020
The company this month secured backing from one of the largest and most respected hospitals in the U.S., with a game-changing deal to install multiple ThermalPass temperature scanning devices in Memorial Healthcare System’s flagship South Florida hospital and its six-hospital network.
$PAI has also been making strides with its subsidy Weather Telematics, which:
Launched its Alert Fleet product, a road weather hazard alert system for commercial fleets.
Alert Fleet advises drivers of dangerous conditions, such as black ice or hydroplaning, 200 metres ahead, thus providing time to mitigate risk and avoid accidents
Recent partnership with Propel IT to accelerate commercialization of IT SAAS Fleet Safety Platform
The latter partnership will significantly enhance available real-time data access for drivers and dispatchers.
Michael Lende, Predictiv AI’s CEO and President, breaks down the news:
Posted by AGORACOM
at 9:45 AM on Friday, April 9th, 2021
TORONTO , April 9, 2021 – Predictiv AI Inc. ( TSXV: PAI) (OTC: INOTF) (FSE: 71TA ) (” Predictiv AI ” or the ” Company “), www.predictiv.ai , a software and solutions provider in the artificial intelligence markets, is pleased to announce it has installed multiple ThermalPass temperature scanning devices in Memorial Healthcare System hospital facilities in south Broward County.
Memorial is a leader in providing high-quality healthcare services to South Florida residents through its six-hospital network and various ancillaries throughout South Florida. The initial rollout of units was completed at Memorial Regional Hospital, the flagship facility and one of the largest hospitals in the state and Memorial Regional Hospital South, home of the Rehabilitation Institute.
“With COVID-19 still threatening our community, it’s important for us to continue using technology in a way that will help us maximize our team’s time and provide quality and safe care to our community,” said Dawn de la Vega , MSN, RN, Director of Nursing at Memorial Regional Hospital. “We have integrated ThermalPass, which has helped us eliminate forehead temperature checks and capture core temperature for employees reporting to work in a more efficient manner.”
“It is an honour to be of service to one of America’s top healthcare systems, having garnered many prestigious awards over the years, including having been selected by the American Hospital Association from more than 5,000 hospitals as the national model for improving the health of the community,” said Jason Elmaleh, President of Commersive Solutions, joint venture partner in ThermalPass.
Posted by AGORACOM
at 9:45 AM on Tuesday, March 23rd, 2021
TORONTO , March 23, 2021 /PRNewswire/ – Predictiv AI Inc. (TSXV: PAI) (OTC: INOTF) (FSE: 71TA) (” Predictiv AI ” or the ” Company “), www.predictiv.ai , a software and solutions provider in the artificial intelligence markets is pleased to announce that its wholly-owned subsidiary, Weather Telematics Inc. (” WTX “), has formalized a strategic product integration partnership with Propel IT Inc. (” Propel “).
The new partnership will significantly enhance available real-time data to which drivers and dispatchers can access. WTX’s hyperlocal, advanced road weather hazard alert system warns drivers of impending dangerous conditions such as black ice, poor visibility and hydroplaning.
Propel is a technology and data company that maximizes safety and efficiency in commercial fleets, who have been serving the transportation and logistics industry in the United States for more than 9 years. Propel is focused on improving driver safety, lowering insurance costs, and reducing environmental impact through fuel savings. Once commercially deployed and integrated, the Alert Fleet system will run as a SAAS model with a monthly recurring revenue component proportionate to the number of vehicles within a customer’s fleet.
“Smarter driving to us means preventing and reducing the impact of accidents for drivers and others on the road. By integrating Alert Fleet with our existing software offerings, our users will now have access to unparalleled real-time advanced hazardous road condition alerts which greatly enhances our efforts to save lives and minimize accidents that could otherwise have been preventable,” said Michael Dieschbourg, President of Propel IT.”
“We are very excited and honoured to be working with one of the world’s leading artificial intelligence institutions. We will now be able to accelerate our innovations and scale our team’s productivity while learning new ways to approach projects with new and unique technologies,” said Michael Lende, CEO of Predictiv AI. “The formalization of this relationship is a crucial building block in our growth plans as it allows us to remain asset-light while simultaneously accelerating innovation on our artificial intelligence and deep machine learning-based solutions. We look forward to a long-term association with Waterloo.AI.”
As part of our ongoing efforts to support Waterloo.AI and its partners, we’re very pleased to share information about an event they will be hosting next week – AI Industry Day on Tuesday, March 25th.
The event will be hosted via Microsoft Teams and will be an interactive and informative online event, enabling Industry to get more acquainted with various AI success stories across multi-sectors of the economy. Catering to diverse interests, attendees will have the option to choose from a menu of topics, with one stream focusing on the use of AI within Advanced Manufacturing. Applicable to all sectors, the keynote speaker will deliver the first-hand experience of “The Journey to Implement AI”, and the importance of “Data” in the future of AI. Morning and afternoon presentations are planned around a mid- day networking event amongst attendees, partners, researchers, and the Waterloo AI Eco-System.
Please feel free to check out the agenda below, click the previous link to discover more information about the event and/or additional details about each presentation, and lastly, make sure to register for the event
– it’s completely free and promises to be fun & informative!
Posted by AGORACOM
at 8:35 AM on Thursday, March 18th, 2021
CE Mark received for in vitro diagnostic (IVD) test for the detection of SARS-CoV-2
Rapid results with ease of use – single 20-minute PCR cycle plus 5-minute detection process
High sensitivity – 104.73 c/PCR limit of detection with 95% confidence interval
High specificity – zero cross-reactivity on 19x respiratory infectious disease panel
High robustness – no impact on results from minor changes in process parameters
100% repeatability and laboratory precision observed
Sales launch in Europe planned for April 2021
XPhyto Therapeutics Corp. (CSE:XPHY)(OTC:XPHYF)(FSE:4XT) (“XPhyto” or the “Company”), and its exclusive German diagnostics development partner, 3a-diagnostics GmbH (“3a”), are pleased to announce the European approval of its point-of-care SARS-CoV-2 (COVID-19) RT-PCR test system (“Covid-ID Lab”). Covid-ID Lab is now registered within the European Union as a commercial in vitro diagnostic (CE-IVD) test.
“Our test is one of the fastest PCR-based COVID-19 tests currently approved. With a sample collection to result time of 25 minutes, Covid-ID Lab combines the speed of a rapid screening test with the accuracy of a PCR diagnostic,” said Hugh Rogers, CEO and Director of XPhyto. “Covid-ID Lab is designed for point-of-care testing, particularly in satellite and small-scale labs, such as transportation hubs, borders, care facilities, schools, pharmacies, and hospitality settings.”
Covid-ID Lab is a multiplex viral RNA probe kit based on the reverse transcriptase-polymerase chain reaction (RT-PCR) method. For assay performance, Covid-ID Lab requires only a single 20-minute PCR thermal cycle without prior RNA extraction as part of the sample preparation. Many widely available standard PCR instruments are suitable to run the test. Results are collected after the PCR cycle via easy-to-read optical indicator strips on a simple fluidics platform. The elimination of RNA extraction for sample preparation reduces the risk of cross-contamination and minimizes the need for lab materials and trained personnel. The rapid results, minimal laboratory equipment, and ease of use are expected to translate into reduced operating costs, greater convenience and portability.
During validation of the assay, the limit of detection for SARS-CoV-2 RNA was determined to be 104.73 c/PCR within a 95% confidence interval. Specificity of 100% against 19 other pathogens of serious respiratory infections was demonstrated on a respiratory verification panel. Precision was determined through evaluation of variance of the analysis results due to random deviations, a repeatability/intra-assay precision evaluation (same lab, user, equipment, etc.), and a laboratory precision evaluation (different lab, user, equipment, etc.). Robustness was measured by evaluation of the impact of minor changes on process parameters (transport medium, PCR cycler model, ramp rate, template volume, hybridization mixing ratio, etc.). The validation studies were carried out accordingly to ICH Q2 (R1) Validation of Analytical Procedures: Text and Methodology and VQ-015 Validation of Methods, European Medicines Agency. The quality management system was in accordance with EN ISO 13485: 2016 and EN ISO 9001: 2015.
Posted by AGORACOM
at 10:36 AM on Tuesday, March 16th, 2021
TORONTO , March 16, 2021 /PRNewswire/ – Predictiv AI Inc. (TSXV: PAI) (OTC: INOTF) (FSE: 71TA) (” Predictiv AI ” or the ” Company “), a software and solutions provider in the artificial intelligence markets is pleased to announce its dynamic new partnership with the Waterloo Artificial Intelligence Institute (“Waterloo.AI”) at the University of Waterloo . This partnership will allow Predictiv AI’s subsidiary, AI Labs Inc. (“AI Labs”), to pursue its various innovations through leveraging Waterloo.AI as an extension of the Predictiv AI team.
The collaboration will allow access to the world’s top artificial intelligence resources, creating much greater bandwidth in ideation, research, and development of solutions for real-world problems. Predictiv AI also looks forward to participating in and supporting Waterloo.AI events and introducing other synergistic partners to the program. Beyond having access to an unparalleled talent pool of academics and their teams for research and development, the partnership also provides for round table participation amongst Waterloo.AI partners.
“We are thrilled to have Predictiv AI join as a partner with Waterloo,” said Harold Godwin , Managing Director of Waterloo.AI. “This is a very exciting time for our university and Waterloo.AI, and we are grateful for the interest and ongoing support of our partners, including our newest, Predictiv AI.”
“We are very excited and honoured to be working with one of the world’s leading artificial intelligence institutions. We will now be able to accelerate our innovations and scale our team’s productivity while learning new ways to approach projects with new and unique technologies,” said Michael Lende, CEO of Predictiv AI.
Posted by AGORACOM
at 8:05 AM on Thursday, March 4th, 2021
Rebranding Reflects XPhyto’s Commitment To Operational Achievement
Product Development Advance From The Lab To The Clinic
Cusp Of Two Major Commercial Milestones Related To Our Rapid Point-Of-Care COVID-19 PCR Test System
A Bioscience Accelerator At The Leading-Edge Of The Life Science Industry
XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) (“XPhyto” or the “Company”), is pleased to announce that the Company has completed a corporate rebranding and launched a new website which can be viewed at www.xphyto.com.
The rebranding decision reflects the Company’s commitment to operational achievement in 2021 as a number of product development programs advance from the laboratory to the clinic. As a bioscience accelerator at the leading-edge of the life science industry, XPhyto is targeting value creation through commercialization of its development pipeline and focused investment in impact driven innovation.
“The Company is excited to introduce a fresh look at such a pivotal point in our business growth,” said Hugh Rogers, CEO & Director of XPhyto. “With all technical requirements fulfilled, we are on the cusp of two major commercial milestones related to our rapid point-of-care COVID-19 PCR test system. With expected ISO certification and CE-IVD approval pending, we are excited to enter the next phase of our business with a positive, crisp and energetic new image.”
The Company will provide further information and updates in due course. The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 pandemic. Further, its COVID-19 related test products are not yet approved and are still subject to risks associated with the regulatory approval process.
Posted by AGORACOM
at 8:05 AM on Wednesday, February 24th, 2021
Placed First Order for its Rapid Point-Of-Care COVID-19 Test System
9600 Individual Tests Ordered
Mid-March Delivery
Additional Pandemic-Focused Biosensors in Development
XPhyto Therapeutics. (CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) (“XPhyto” or the “Company“), is pleased to announce that it has placed the first order for its rapid point-of-care SARS-CoV-2 (COVID-19) RT-PCR test system (“Covid-ID Lab”) from its exclusive diagnostic development partner, 3a-diagnostics GmbH (“3a”).
The first order of Covid-ID Lab is for 9,600 individual tests, which are packaged in 200 kits of 48 tests each. Delivery of the first order is expected by mid-March 2021 and will be primarily used to supply prospective distribution partners and licensees and their respective government regulators with test samples for review and evaluation. The tests will be manufactured in the German state of Baden-Württemberg.
“We are pleased to report that all steps towards the launch of Covid-ID Lab remain on track within an ambitious timeline,” said Hugh Rogers, CEO, and Director of XPhyto. “Our experienced market launch team is working quickly to bring the product to market, as well as to establish licensing and distribution partnerships. We are confident that Covid-ID Lab, as a 25-minute PCR test with minimal technical and personnel requirements, will be a stand-out product in the COVID-19 test market.”
Covid-ID Lab was designed to be a rapid, accurate, and robust COVID-19 test system with reduced operating costs and increased convenience and portability. XPhyto expects 3a to receive ISO 13485 medical device manufacturer approval by the end of February and European regulatory approval as a commercial in vitro diagnostic device (CE-IVD) for Covid-ID Lab by early March. Initial commercial manufacturing is planned for Germany, with additional capacity in other jurisdictions to follow. The sales launch in Europe is targeted for April 2021. XPhyto is currently in discussions with potential distribution and wholesale partners in Europe and the Middle East.
XPhyto and 3a are also developing a portfolio of oral biosensor screening tests for detection of bacterial and viral infectious diseases, including influenza A, group A strep, stomatitis, periimplantitis, and periodontitis. Additional pandemic-focused biosensors are in development, specifically for H1N1 (swine flu) and H5N1 (avian flu). The Company is planning the commercial launch of its first biosensor product in the second half of 2021.
